Evaluation of Immunoassay Performance for the Detection of Opioids in Urine
The Journal of Applied Laboratory Medicine · 2025
DOI: 10.1093/jalm/jfae169 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift The Journal of Applied Laboratory Medicine, 2025. Verfasst von Michael E Walsh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States. Hauptthemen laut MEDLINE: Substance Abuse Detection, Analgesics, Opioid. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Immunoassay drug screens provide rapid analysis of urine for the presence of therapeutics and drugs of abuse. Compared to definitive (confirmatory) methods, immunoassays are prone to false-positive and -negative results. Laboratories generally rely on manufacturers’ claims regarding method sensitivity and specificity; few have the resources to independently verify performance. In this study, we review the performance of our opioid immunoassay drug screens in comparison to a definitive method.
Methods
Results of 859 urine samples tested via opioid immunoassay screens for buprenorphine, fentanyl, methadone metabolite (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine; EDDP), opiates, and oxycodone were compared to definitive results obtained via liquid chromatography–tandem mass spectrometry (LC-MS/MS). The data examined here included multiple samples from individual patients. Our quantitative LC-MS/MS method includes 19 opioid compounds (parent drugs plus metabolites).
Results
Immunoassay sensitivity and specificity ranged from 96% to 100% and 84% to 99%, respectively. The sensitivity and specificity of these screens were similar to manufacturers’ claims with some exceptions. The opiates immunoassay had poor performance when limiting the comparison to its target compound, morphine, but improved when including all compounds listed in the manufacturer’s instructions for use (IFU). While demonstrating good sensitivity, the buprenorphine immunoassay demonstrated lower specificity than stated in the IFU.
Conclusions
The opioid immunoassay screens in use at our facility compared favorably to a definitive LC-MS/MS method. The urine fentanyl screen had the lowest sensitivity (96%) and had a specificity of 97%. The urine buprenorphine assay was the least specific (84%) and had a sensitivity of 99%.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, United States.
- Department of Pathology and Laboratory Medicine, The Geisel School of Medicine at Dartmouth, Hanover, NH, United States.
ORCID-Profile: Michael T Kelliher, Mark A Cervinski
Zitieren
APA
Walsh, M. E., Kelliher, M. T., Hubbard, J. A., & Cervinski, M. A. (2025). Evaluation of Immunoassay Performance for the Detection of Opioids in Urine. The Journal of Applied Laboratory Medicine. https://doi.org/10.1093/jalm/jfae169
Vancouver
Walsh ME, Kelliher MT, Hubbard JA, Cervinski MA. Evaluation of Immunoassay Performance for the Detection of Opioids in Urine. The Journal of Applied Laboratory Medicine. 2025. doi:10.1093/jalm/jfae169
BibTeX
@article{Walsh2025,
author = {Walsh, Michael E and Kelliher, Michael T and Hubbard, Jacqueline A and Cervinski, Mark A},
title = {Evaluation of Immunoassay Performance for the Detection of Opioids in Urine},
journal = {The Journal of Applied Laboratory Medicine},
year = {2025},
doi = {10.1093/jalm/jfae169}
}
EUVIMED